MCID: LYM026
MIFTS: 62

Lymphoblastic Leukemia malady

Categories: Cancer diseases, Immune diseases, Genetic diseases, Rare diseases, Blood diseases

Aliases & Classifications for Lymphoblastic Leukemia

Aliases & Descriptions for Lymphoblastic Leukemia:

Name: Lymphoblastic Leukemia 12 14
Precursor Cell Lymphoblastic Leukemia Lymphoma 69
Acute Lymphocytic Leukemia 69
Leukemia, Lymphoid 42
Lymphoid Leukemia 69

Classifications:



External Ids:

Disease Ontology 12 DOID:1037
ICD10 33 C91 C91.9 C91.90
ICD9CM 35 204 204.9
MeSH 42 D007945
NCIt 47 C7539
UMLS 69 C0023448

Summaries for Lymphoblastic Leukemia

Disease Ontology : 12 A leukemia that has material basis in lymphoblasts (immature white blood cells).

MalaCards based summary : Lymphoblastic Leukemia, also known as precursor cell lymphoblastic leukemia lymphoma, is related to acute lymphocytic leukemia and hemophagocytic lymphohistiocytosis, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Lymphoblastic Leukemia is FLT3 (Fms Related Tyrosine Kinase 3), and among its related pathways/superpathways are Mesodermal Commitment Pathway and HTLV-I infection. The drugs Arranon and Blincyto have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and myeloid, and related phenotypes are hematopoietic system and immune system

Related Diseases for Lymphoblastic Leukemia

Diseases in the Lymphoblastic Leukemia family:

Leukemia, Acute Lymphoblastic 2 Leukemia, Acute Lymphoblastic
Leukemia, Acute Lymphoblastic 3

Diseases related to Lymphoblastic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 381)
id Related Disease Score Top Affiliating Genes
1 acute lymphocytic leukemia 32.5 AFF1 FLT3 JAK2 MLLT1 RUNX1 TCF3
2 hemophagocytic lymphohistiocytosis 30.2 FLT3 IKZF1 JAK2 NOTCH1 RUNX1
3 acute lymphoblastic leukemia, childhood 12.3
4 b-cell childhood acute lymphoblastic leukemia 12.2
5 leukemia, acute lymphoblastic 12.2
6 precursor t-cell acute lymphoblastic leukemia 12.1
7 acute pre-b-cell lymphoblastic leukemia 12.1
8 acute non lymphoblastic leukemia 12.0
9 acute lymphoblastic leukemia congenital sporadic aniridia 11.9
10 precursor lymphoblastic lymphoma/leukemia 11.6
11 t-cell childhood acute lymphocytic leukemia 11.5
12 lymphoblastic lymphoma 11.3
13 bone marrow necrosis 11.3
14 chronic lymphocytic leukemia 11.3
15 leukemia 11.3
16 leukemia, acute lymphoblastic 3 11.2
17 leukemia, acute myeloid 11.2
18 acute t cell leukemia 11.2
19 b-cell adult acute lymphocytic leukemia 11.2
20 t-cell adult acute lymphocytic leukemia 11.1
21 null-cell leukemia 11.1
22 lymphoid leukemia 10.9
23 precursor b lymphoblastic lymphoma/leukemia 10.9
24 precursor t-lymphoblastic lymphoma/leukemia 10.9
25 childhood precursor t-lymphoblastic lymphoma/leukemia 10.9
26 lymphoma 10.6
27 x-linked adrenal hypoplasia congenita 10.3 IKZF1 RUNX1
28 acute myocardial infarction 10.3 CDKN2A FLT3 RUNX1
29 fetal nicotine spectrum disorder 10.3 IKZF1 PBX1
30 myeloid leukemia 10.3
31 unilateral hemispheric polymicrogyria 10.3 FLT3 RUNX1
32 bifid uvula 10.3 CDKN2A FLT3 NOTCH1 TLX3
33 glucocorticoid resistance 10.3
34 plasmodium vivax malaria 10.2 PBX1 RUNX1
35 familial hyperaldosteronism 10.2 FLT3 JAK2 RUNX1
36 adult acute lymphocytic leukemia 10.2 CDKN2A NOTCH1 RUNX1 TAL2 TLX3
37 colorectal adenoma 10.2 FLT3 JAK2 RUNX1
38 hematopoietic stem cell transplantation 10.2
39 childhood leukemia 10.2
40 acute leukemia 10.2
41 hyperphosphatasia with mental retardation syndrome 2 10.2 AFF1 CDKN2A FLT3 IKZF1 PBX1 RUNX1
42 prostate cancer 10.2
43 actinobacillosis 10.2 FLT3 JAK2 RUNX1
44 down syndrome 10.1
45 sarcoma 10.1
46 acute respiratory distress syndrome 10.1 FLT3 JAK2
47 thrombosis 10.1
48 myelodysplastic syndrome 10.1
49 mixed astrocytoma-ependymoma-oligodendroglioma 10.0 ARID5B MLLT1 PBX1 RUNX1 TCF3
50 osteonecrosis 10.0

Comorbidity relations with Lymphoblastic Leukemia via Phenotypic Disease Network (PDN):


Deficiency Anemia Leukemia, B-Cell, Chronic
Neutropenia

Graphical network of the top 20 diseases related to Lymphoblastic Leukemia:



Diseases related to Lymphoblastic Leukemia

Symptoms & Phenotypes for Lymphoblastic Leukemia

UMLS symptoms related to Lymphoblastic Leukemia:


angina pectoris, chest pain, edema

MGI Mouse Phenotypes related to Lymphoblastic Leukemia:

44 (show all 16)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.45 LYL1 MLLT1 NOTCH1 PBX1 RUNX1 TAL2
2 immune system MP:0005387 10.41 AFF1 ARID5B BAX CDKN2A CRLF2 FBXW7
3 cellular MP:0005384 10.37 ARID5B BAX CDKN2A CRLF2 FBXW7 FLT3
4 endocrine/exocrine gland MP:0005379 10.37 PBX1 RUNX1 TCF3 JAK2 LCK NOTCH1
5 growth/size/body region MP:0005378 10.36 NOTCH1 PBX1 RUNX1 TAL2 TCF3 AFF1
6 mortality/aging MP:0010768 10.3 AFF1 ARID5B BAX CDKN2A CRLF2 FBXW7
7 homeostasis/metabolism MP:0005376 10.29 ARID5B BAX CDKN2A CRLF2 FBXW7 FLT3
8 embryo MP:0005380 10.19 CDKN2A FBXW7 JAK2 LCK LMO2 NOTCH1
9 digestive/alimentary MP:0005381 10.15 CRLF2 FBXW7 IKZF1 NOTCH1 PBX1 TLX3
10 integument MP:0010771 10.13 FBXW7 IKZF1 JAK2 LMO2 NOTCH1 PBX1
11 neoplasm MP:0002006 10.1 IKZF1 JAK2 LMO2 MLLT1 NOTCH1 RUNX1
12 liver/biliary system MP:0005370 10.06 CDKN2A IKZF1 JAK2 LMO2 MLLT1 NOTCH1
13 nervous system MP:0003631 10 AFF1 BAX CDKN2A FBXW7 TCF3 TLX3
14 renal/urinary system MP:0005367 9.7 ARID5B BAX LMO2 MLLT1 NOTCH1 PBX1
15 respiratory system MP:0005388 9.61 BAX CDKN2A CRLF2 FBXW7 IKZF1 NOTCH1
16 skeleton MP:0005390 9.28 ARID5B BAX CDKN2A FLT3 JAK2 LMO2

Drugs & Therapeutics for Lymphoblastic Leukemia

FDA approved drugs:

(show all 7)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Arranon 17 46 NELARABINE GlaxoSmithKline Approved October 2005
2
Blincyto 17 46 BLINATUMOMAB Amgen Approved December 2014
3
Clolar 17 46 CLOFARABINE Genzyme Approved December, 2004
4
Erwinaze 17 46 asparaginase Erwinia chrysanthemi Eusa Pharma Approved November of 2011
5
Iclusig 17 46 PONATINIB HYDROCHLORIDE Ariad Pharmaceuticals Approved December 2012
6
Marqibo 17 46 VINCRISTINE SULFATE Talon Therapeutics Approved August 2012
7
Sprycel 17 46 DASATINIB Bristol-Myers Squibb Approved June 2006

Drugs for Lymphoblastic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 710)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Asparaginase Approved Phase 4,Phase 3,Phase 2,Phase 1 9015-68-3
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
3
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4 6253
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
5
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
6
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
7
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 130167-69-0
8
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2068-78-2, 57-22-7 5978
9
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 58957-92-9 42890
10
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
11
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
12
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
13
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
14
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-61-7 60961
15
Pentostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53910-25-1 40926 439693
16
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 20830-81-3 30323
17
Cladribine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 4291-63-8 20279
18
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
19
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
20
Teniposide Approved Phase 4,Phase 3,Phase 2 29767-20-2 34698
21
Thioguanine Approved Phase 4,Phase 3,Phase 2,Phase 1 154-42-7 2723601
22
Vindesine Approved Phase 4,Phase 3,Phase 2 59917-39-4, 53643-48-4 40839
23
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 3778-73-2 3690
24
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
25
Chlorambucil Approved Phase 4,Phase 3,Phase 2,Phase 1 305-03-3 2708
26
Vidarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 24356-66-9 32326 21704
27
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 5754 657311
28
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 65271-80-9 4212
29
Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
30
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 55-98-1 2478
31
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
32
Gemcitabine Approved Phase 4,Phase 2,Phase 1 95058-81-4 60750
33
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
34
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 302962-49-8 3062316
35
Valganciclovir Approved, Investigational Phase 4,Phase 2 175865-60-8 64147
36
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
37
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
38
Oprelvekin Approved, Investigational Phase 4,Phase 1,Phase 2 145941-26-0
39
Daclizumab Approved, Investigational Phase 4,Phase 2,Phase 1 152923-56-3
40
Menthol Approved Phase 4 2216-51-5 16666
41
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
42
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
43
Blinatumomab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 853426-35-4
44
Nicotine Approved Phase 4 54-11-5 942 89594
45
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2 1397-89-3 14956 5280965
46
Micafungin Approved, Investigational Phase 4,Phase 2 235114-32-6 3081921 477468
47
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
48
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 54575, 6560146 143
49
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
50
Butyric Acid Experimental Phase 4,Phase 3,Phase 2,Phase 1 107-92-6 264

Interventional clinical trials:

(show top 50) (show all 2779)
id Name Status NCT ID Phase
1 Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4
2 German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00198978 Phase 4
3 Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4
4 Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Unknown status NCT01990807 Phase 4
5 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Unknown status NCT00198991 Phase 4
6 Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses Unknown status NCT00192673 Phase 4
7 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4
8 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4
9 Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4
10 A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) Completed NCT01056510 Phase 4
11 Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America Completed NCT02559583 Phase 4
12 LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia Completed NCT00526409 Phase 4
13 PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Completed NCT00494897 Phase 4
14 Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia Completed NCT01358253 Phase 4
15 Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia Completed NCT00199095 Phase 4
16 Antiviral Treatment of Chronic Lymphocytic Leukemia Completed NCT01255644 Phase 4
17 A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status Completed NCT01271010 Phase 4
18 LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive Completed NCT00526305 Phase 4
19 A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status Completed NCT01283386 Phase 4
20 Intensified Conditioning Regimen With High-Dose-Etoposide for Allo-HSCT for Adult Acute Lymphoblastic Leukemia Completed NCT01457040 Phase 4
21 ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
22 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93) Completed NCT00199069 Phase 4
23 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99) Completed NCT00199056 Phase 4
24 Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab Completed NCT00199004 Phase 4
25 A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Completed NCT00220311 Phase 4
26 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4
27 Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL) Completed NCT00802737 Phase 4
28 LAL-BR/2001: Study Treatment to Low Risk ALL Completed NCT00526175 Phase 4
29 The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL Completed NCT00919321 Phase 4
30 Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL Completed NCT02314273 Phase 4
31 The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents Completed NCT02953730 Phase 4
32 Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy Completed NCT00524407 Phase 4
33 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4
34 German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults Completed NCT00199017 Phase 4
35 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
36 Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Completed NCT00361140 Phase 4
37 Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Completed NCT01418430 Phase 4
38 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
39 The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia Recruiting NCT00846703 Phase 4
40 Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years) Recruiting NCT01366898 Phase 4
41 Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS Recruiting NCT01540812 Phase 4
42 Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study Recruiting NCT02894645 Phase 4
43 Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE Recruiting NCT01491763 Phase 4
44 PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years Recruiting NCT01358201 Phase 4
45 Study on Two Different Formulations of 6-mercaptopurine. Tablet Versus Oral Liquid Recruiting NCT01906671 Phase 4
46 HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL Recruiting NCT01873807 Phase 4
47 Vaccinating Children After Chemotherapy Recruiting NCT02447718 Phase 4
48 ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
49 Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Recruiting NCT02036489 Phase 4
50 ATG Could Improve the Outcome Of Hematopoietic Stem Cell Transplant in Patients With Highly Aggressive T Cell Tumors Recruiting NCT02290132 Phase 4

Search NIH Clinical Center for Lymphoblastic Leukemia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: leukemia, lymphoid

Genetic Tests for Lymphoblastic Leukemia

Anatomical Context for Lymphoblastic Leukemia

MalaCards organs/tissues related to Lymphoblastic Leukemia:

39
T Cells, B Cells, Myeloid, Bone, Bone Marrow, B Lymphoblasts, Endothelial

Publications for Lymphoblastic Leukemia

Articles related to Lymphoblastic Leukemia:

(show top 50) (show all 3309)
id Title Authors Year
1
Association of ARID5B gene variants with acute lymphoblastic leukemia in Yemeni children. ( 28381164 )
2017
2
Neutropenic acute acalculous cholecystitis (AAC) in a 12-year-old boy with T-acute lymphoblastic leukemia successfully managed with conservative treatment. ( 28085529 )
2017
3
Utility of the serum galactomannan assay for the diagnosis of invasive aspergillosis in children with acute lymphoblastic leukemia. ( 27815226 )
2017
4
Major molecular response prior to allogeneic hematopoietic stem cell transplantation predicts better outcome in adult Philadelphia-positive acute lymphoblastic leukemia in first remission. ( 28092348 )
2017
5
Near-triploid B lymphoblastic leukemia with Burkitt-like morphology. ( 28082295 )
2017
6
Low dose of 2-deoxy-D-glucose kills acute lymphoblastic leukemia cells and reverses glucocorticoid resistance via N-linked glycosylation inhibition under normoxia. ( 28415682 )
2017
7
Genome-wide study links PNPLA3 variant with elevated hepatic transaminase after acute lymphoblastic leukemia therapy. ( 28090653 )
2017
8
Survival Outcome of Filipino Children With Acute Lymphoblastic Leukemia Treated With Modified Berlin-Frankfurt-Muenster/Hong Kong Acute Lymphoblastic Leukemia (BFM95/HKALL97) Protocol in a Tertiary General Hospital From January 2005 to December 2009: A Retrospective Cohort Study. ( 28085747 )
2017
9
Tyrosine Kinase Inhibitor for Treatment of Adult Allogeneic Hematopoietic Stem Cell Transplantation Candidate with Philadelphia-Positive Acute Lymphoblastic Leukemia. ( 28091401 )
2017
10
Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes. ( 28063722 )
2017
11
Oncogenic ZEB2 activation drives sensitivity towards KDM1A inhibition in T-cell acute lymphoblastic leukemia. ( 28069602 )
2017
12
Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia. ( 28074072 )
2017
13
New diagnosis of atypical ataxia-telangiectasia in a 17-year-old boy with T-cell acute lymphoblastic leukemia and a novel ATM mutation. ( 28123174 )
2017
14
BCR-ABL translocation as a favorable prognostic factor in elderly acute lymphoblastic leukemia patients in potent tyrosine kinase era. ( 28082339 )
2017
15
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia. ( 28082340 )
2017
16
Epratuzumab and Blinatumomab as Therapeutic Antibodies for Treatment of Pediatric Acute Lymphoblastic Leukemia: Current Status and Future Perspectives. ( 28088906 )
2017
17
JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias. ( 28484265 )
2017
18
Salvage therapy for children with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. ( 28084041 )
2017
19
The Behavior Rating Inventory of Executive Function (BRIEF) to Identify Pediatric Acute Lymphoblastic Leukemia (ALL) Survivors At Risk for Neurocognitive Impairment. ( 28085741 )
2017
20
Reversible Cerebral Vasoconstriction Syndrome during Chemotherapy for Acute Lymphoblastic Leukemia. ( 27769550 )
2017
21
Corrigendum: Targeting High Dynamin-2 (DNM2) Expression by Restoring Ikaros Function in Acute Lymphoblastic Leukemia. ( 28074872 )
2017
22
Sinusoidal Obstruction Syndrome During Maintenance Therapy for Acute Lymphoblastic Leukemia With 6-Mercaptopurine and Methotrexate: A Pediatric Case Report. ( 28085749 )
2017
23
Severe hypertriglyceridemia during treatment of acute lymphoblastic leukemia associated with type III hyperlipoproteinemia. ( 28371240 )
2017
24
Nosocomial legionellosis and invasive aspergillosis in a child with T-lymphoblastic leukemia. ( 28529020 )
2017
25
KMT2E-ASNS: a novel relapse-specific fusion gene in early T-cell precursor acute lymphoblastic leukemia. ( 28069604 )
2017
26
Evaluation of functional RAGE gene polymorphisms in childhood acute lymphoblastic leukemia-A case-control study from Iran. ( 28045617 )
2017
27
CREB knockdown inhibits growth and induces apoptosis in human pre-B acute lymphoblastic leukemia cells through inhibition of prosurvival signals. ( 28063408 )
2017
28
Long-term brain structural magnetic resonance imaging and cognitive functioning in children treated for acute lymphoblastic leukemia with high-dose methotrexate chemotherapy alone or combined with CNS radiotherapy at reduced total dose to 12A Gy. ( 28074235 )
2017
29
Hypertriglyceridemia during asparaginase treatment in children with acute lymphoblastic leukemia correlates with antithrombin activity in adolescents. ( 28440015 )
2017
30
Network-based expression analysis reveals key genes related to glucocorticoid resistance in infant acute lymphoblastic leukemia. ( 27798768 )
2017
31
Morphoproteomics Identifies SIRT1 and EZH2 Pathways as Commonalities in B-cell Acute Lymphoblastic Leukemia: Pathogenetic Implications and Opportunities for Therapeutic Intervention. ( 28249909 )
2017
32
miR-181a-5p, an inducer of Wnt-signaling, facilitates cell proliferation in acute lymphoblastic leukemia. ( 28184923 )
2017
33
Genomic profiling of Acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis. ( 28196983 )
2017
34
Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome. ( 28461505 )
2017
35
Interleukin-23 Receptor Gene Variants in Acute Lymphoblastic Leukemia and Their Relation to Prognostic Factors. ( 28341819 )
2017
36
TSER polymorphism is not associated with risk of pediatric acute lymphoblastic leukemia: A meta-analysis. ( 28207544 )
2017
37
Screening ABL1 kinase domain mutations in patients with de novo Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). ( 27658493 )
2016
38
A prospective evaluation of minimal residual disease as risk stratification for CCLG-ALL-2008 treatment protocol in pediatric B precursor acute lymphoblastic leukemia. ( 27212157 )
2016
39
Pyr3, a TRPC3 channel blocker, potentiates dexamethasone sensitivity and apoptosis in acute lymphoblastic leukemia cells by disturbing Ca(2+) signaling, mitochondrial membrane potential changes and reactive oxygen species production. ( 27179991 )
2016
40
Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia. ( 27019981 )
2016
41
Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. ( 27090891 )
2016
42
Congenital B-lymphoblastic leukemia with a cryptic MLL rearrangement and post-treatment evolution to mixed phenotype acute leukemia. ( 27547725 )
2016
43
Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia. ( 27067989 )
2016
44
Osteonecrosis is unrelated to hip anatomy in children with acute lymphoblastic leukemia. ( 28035753 )
2016
45
MiR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia. ( 27649261 )
2016
46
Association of Genetic Variants in ARID5B, IKZF1 and CEBPE with Risk of Childhood de novo B-Lineage Acute Lymphoblastic Leukemia in India. ( 27644650 )
2016
47
Mycobacterium chelonae Infection Involving a Percutaneous Gastrostomy Tube Tract in a Seven-year-old Child With Acute Lymphoblastic Leukemia. ( 26756265 )
2016
48
Eye on the B-ALL: B-cell receptor repertoires reveal persistence of numerous B-lymphoblastic leukemia subclones from diagnosis to relapse. ( 27211266 )
2016
49
Speed of leukemia development and genetic diversity in xenograft models of T cell acute lymphoblastic leukemia. ( 27191650 )
2016
50
MHC Class I Chain-Related Gene A (MICA) Donor-Recipient Mismatches and MICA-129 Polymorphism in Unrelated Donor Hematopoietic Cell Transplantations Has No Impact on Outcomes in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome: A Center for International Blood and Marrow Transplant Research Study. ( 27987385 )
2016

Variations for Lymphoblastic Leukemia

Expression for Lymphoblastic Leukemia

Search GEO for disease gene expression data for Lymphoblastic Leukemia.

Pathways for Lymphoblastic Leukemia

GO Terms for Lymphoblastic Leukemia

Cellular components related to Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.65 ARID5B CDKN2A FBXW7 IKZF1 JAK2 MLLT1
2 nucleus GO:0005634 9.55 AFF1 ARID5B BAX CDKN2A FBXW7 FLT3

Biological processes related to Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.93 CDKN2A LYL1 NOTCH1 RUNX1 TCF3
2 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.91 CDKN2A IKZF1 LMO2 NOTCH1 PBX1 RUNX1
3 regulation of cell proliferation GO:0042127 9.78 JAK2 LCK NOTCH1 PBX1
4 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.7 ARID5B JAK2 TCF3
5 hemopoiesis GO:0030097 9.67 FLT3 LCK RUNX1
6 B cell differentiation GO:0030183 9.61 FLT3 LYL1 TCF3
7 negative regulation of neuron differentiation GO:0045665 9.58 NOTCH1 PBX1 TLX3
8 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.51 BAX JAK2
9 somatic stem cell division GO:0048103 9.46 CDKN2A NOTCH1
10 regulation of transcription, DNA-templated GO:0006355 9.4 AFF1 ARID5B CDKN2A IKZF1 LYL1 MLLT1
11 leukocyte homeostasis GO:0001776 9.26 BAX FLT3
12 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.26 BAX CDKN2A JAK2 LCK
13 apoptotic process involved in embryonic digit morphogenesis GO:1902263 9.16 BAX NOTCH1
14 transcription, DNA-templated GO:0006351 10.02 ARID5B CDKN2A IKZF1 LYL1 MLLT1 NOTCH1

Molecular functions related to Lymphoblastic Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 AFF1 ARID5B BAX CDKN2A FBXW7 FLT3
2 DNA binding GO:0003677 9.85 ARID5B CDKN2A IKZF1 LYL1 MLLT1 PBX1
3 phosphatidylinositol 3-kinase binding GO:0043548 9.32 JAK2 LCK
4 transcriptional activator activity, RNA polymerase II transcription factor binding GO:0001190 9.26 LMO2 NOTCH1
5 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.02 ARID5B LMO2 LYL1 RUNX1 TAL2

Sources for Lymphoblastic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....